Evidence map›Paper›PMID 42630676›Full record

ReviewOncology research2026

The Role of Mitochondrial ROS in Neoplastic Transformations, Progression and Therapeutic Targeting.

Bharath Kumar Velmurugan, Shu Hui Lin, Chih-Yang Huang, Ming-Ju Hsieh, Rathinasamy Baskaran

Abstract readReview
In one paragraph

Review in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bharath Kumar VelmuruganMaitocon Laboratory, Tirupur, Tamil Nadu, India.
Shu Hui LinDepartment of Surgical Pathology, Changhua Christian Hospital, Changhua, Taiwan.
Chih-Yang HuangDepartment of Precision Chinese Herbal Medicine and Molecular Medicine Research, E-Da Cancer Hospital, E-Da Healthcare Group, Kaohsiung, Taiwan.
Ming-Ju HsiehGraduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Rathinasamy BaskaranCardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitochondria are central regulators of cellular metabolism and survival and play a pivotal role in cancer development and progression through the production of reactive oxygen species (ROS), control of calcium homeostasis, regulation of autophagy, and modulation of cell death pathways. Mitochondria-derived ROS (mtROS) act as signaling mediators that influence tumor initiation, proliferation, metabolic reprogramming, metastasis, and therapeutic resistance by altering redox homeostasis, damaging mitochondrial DNA, and reshaping the tumor microenvironment. In addition to meeting the bioenergetic and biosynthetic requirements of rapidly proliferating cancer cells, mitochondrial metabolism modulates immune responses and supports cancer cell adaptation to hypoxia and nutrient deprivation. Accumulating evidence also highlights the dual role of mtROS, which can promote tumor progression at moderate levels yet trigger oxidative stress-induced cell death when excessively increased, making mitochondrial redox signaling an attractive therapeutic target. This review summarizes the major sources and regulation of mtROS, their involvement in cancer-associated signaling pathways, mitochondrial calcium dynamics, metabolic adaptations, and resistance to anticancer therapies, and discusses current and emerging mitochondrial-targeted strategies aimed at exploiting mtROS signaling to improve cancer treatment outcomes.

Indexed as

Cell Transformation, NeoplasticMitochondriaNeoplasmsReactive Oxygen SpeciesAnimalsDisease ProgressionHumansMetabolic ReprogrammingMolecular Targeted TherapyOxidative StressSignal TransductionTumor MicroenvironmentReactive Oxygen SpeciesCancerelectron transport chainmitochondriaoncometabolitesreactive oxygen species

Identifiers

PMID42630676
PMCPMC13494497

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.